相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
M. -R. Taskinen et al.
DIABETES OBESITY & METABOLISM (2011)
Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin
R. Sechaud et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin
U. Graefe-Mody et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
T. Forst et al.
DIABETIC MEDICINE (2010)
The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
Stefan Blech et al.
DRUG METABOLISM AND DISPOSITION (2010)
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
Carolyn F. Deacon et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
Abd A. Tahrani et al.
ADVANCES IN THERAPY (2009)
Binding to Dipeptidyl Peptidase-4 Determines the Disposition of Linagliptin (BI 1356) - Investigations in DPP-4 Deficient and Wildtype Rats
Silke Retlich et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2009)
Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
E. U. Graefe-Mody et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
T. Heise et al.
DIABETES OBESITY & METABOLISM (2009)
Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib
Jules I. Schwartz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers
S. Huettner et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes
Matthias Eckhardt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers
Yon-Ling He et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay
PV Balimane et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2005)
Association of serum digoxin concentration and outcomes in patients with heart failure
SS Rathore et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Organic anion-transporting polypeptide (OATP) transporter family and drug disposition
RB Kim
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2003)
分享论文
